ArticleInternational journal of medical sciences2023
18β-glycyrrhetinic Acid Modulated Autophagy is Cytotoxic to Breast Cancer Cells.
Article in International journal of medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Pentacyclic Triterpenoid Acids in the Treatment of Breast Cancer.Molecules (Basel, Switzerland) · 2026Review
- A highly biocompatible self-assembled Pt(IV) nanoplatform integrating Nrf2 inhibition for synergistic apoptosis and ferroptosis in hepatocellular carcinoma.Materials today. Bio · 2026Article
- Mechanistic insights into 18β-glycyrrhetinic acid-induced apoptosis in SCC-9 cells revealed by TMT proteomics and network pharmacology.Scientific reports · 2026Article
- Anticancer potential of mangrove derived metabolites: cytotoxicity and phytochemical based studies.BMC complementary medicine and therapies · 2026Article
- 18β-glycyrrhetinic acid inhibits lung adenocarcinoma progression by targeting the MET/AKT signaling axis.Frontiers in cell and developmental biology · 2026Article
- Study on the mechanism of 18β-glycyrrhetinic acid inhibiting the proliferation of renal cancer cells by inducing autophagy through the miR-27a-5p/LC3 axis.Frontiers in oncology · 2026Article
- Neuroprotective Effects ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Potential Anti-Tumorigenic Properties of Diverse Medicinal Plants against the Majority of Common Types of Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Self-Assembled nanoparticles of natural bioactive molecules enhance the delivery and efficacy of paclitaxel in glioblastoma.CNS neuroscience & therapeutics · 2024Article
- Gypsogenin Battling for a Front Position in the Pentacyclic TriterpenesMolecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of endocrine therapy resistance in the luminal A subtype of breast cancer is related to the appearance of protective autophagy. The bioactive component from the root of licorice, 18β-glycyrrhetinic acid (18β-GA), has many antitumor properties. Whether 18β-GA can modulate autophagy to inhibit proliferation of the luminal A subtype is still unclear. The proportion of apoptosis caused by 18β-GA in MCF-7 and T-47D cells was determined using flow cytometry. The autophagy marker, LC3-II conversion, was investigated using Western blotting, and a Premo
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.